SynthesisBritish journal of clinical pharmacology2026
Pharmacokinetics of teicoplanin in paediatric patients-A systematic review of current literature.
Synthesis in British journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pharmacokinetics of teicoplanin in paediatric patients-A systematic review of current literature.British journal of clinical pharmacology · 2026Pooled it
- Antibiotic Prophylaxis and Treatment of Neonatal Group B Streptococcus Disease in the Era of Antimicrobial Resistance.Antibiotics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
BACKGROUND AND
objectiveTeicoplanin is commonly used in children to treat gram-positive infections and is sometimes used off-label prophylactically in surgical or paediatric oncology settings. The pharmacokinetics (PK) of teicoplanin in children exhibit considerable variability, such as in critically ill children or those with renal impairment. This systematic review aims to summarize and evaluate reported PK data and target attainment, identify PK variations and provide dosing recommendations when available.
methodsA systematic literature search was performed in PubMed and Embase, following PRISMA 2020 guidelines. Included studies were randomized controlled trials, nonrandomized controlled trials or prospective/retrospective cohort studies, published up to December 2024, that assessed PK or teicoplanin exposure in children. Data on PK, target attainment, efficacy, and toxicity were extracted.
resultsTwenty-six articles were included in the final analysis, revealing significant PK variability among subgroups (neonates, infants, children aged ≥1 year, children with renal impairment, critically ill children and paediatric oncology patients). This variability is partially explained by covariates such as kidney function, illness and age. In critically ill and paediatric oncology patients, clearance (CL) was higher. Compared with other populations, the volume of distribution (Vd) in critically ill children appeared somewhat higher. A positive correlation between CL and kidney function was identified.
conclusionTeicoplanin PK in children is highly variable, with target trough levels often not achieved, making universal dosing recommendations challenging. Future studies should define indication-dependent targets. Therapeutic drug monitoring could improve clinical efficacy. Defining unbound exposure and its clinical correlates should be a priority for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.